JP7634895B2 - パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 - Google Patents

パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 Download PDF

Info

Publication number
JP7634895B2
JP7634895B2 JP2022522035A JP2022522035A JP7634895B2 JP 7634895 B2 JP7634895 B2 JP 7634895B2 JP 2022522035 A JP2022522035 A JP 2022522035A JP 2022522035 A JP2022522035 A JP 2022522035A JP 7634895 B2 JP7634895 B2 JP 7634895B2
Authority
JP
Japan
Prior art keywords
asp
animals
cells
phagocytes
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022522035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551943A (ja
Inventor
ピーター ノヴァク，
マキシム テムニコフ，
オレクサンドル バラキン，
Original Assignee
ヴェクター ヴィターレ アイピー エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェクター ヴィターレ アイピー エルエルシー filed Critical ヴェクター ヴィターレ アイピー エルエルシー
Publication of JP2022551943A publication Critical patent/JP2022551943A/ja
Priority to JP2024000684A priority Critical patent/JP2024038270A/ja
Application granted granted Critical
Publication of JP7634895B2 publication Critical patent/JP7634895B2/ja
Priority to JP2025113738A priority patent/JP2025148408A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022522035A 2019-10-11 2019-10-11 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 Active JP7634895B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024000684A JP2024038270A (ja) 2019-10-11 2024-01-05 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
JP2025113738A JP2025148408A (ja) 2019-10-11 2025-07-04 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/055770 WO2021071499A1 (en) 2019-10-11 2019-10-11 Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000684A Division JP2024038270A (ja) 2019-10-11 2024-01-05 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物

Publications (2)

Publication Number Publication Date
JP2022551943A JP2022551943A (ja) 2022-12-14
JP7634895B2 true JP7634895B2 (ja) 2025-02-25

Family

ID=68387423

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022522035A Active JP7634895B2 (ja) 2019-10-11 2019-10-11 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
JP2024000684A Withdrawn JP2024038270A (ja) 2019-10-11 2024-01-05 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
JP2025113738A Pending JP2025148408A (ja) 2019-10-11 2025-07-04 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024000684A Withdrawn JP2024038270A (ja) 2019-10-11 2024-01-05 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
JP2025113738A Pending JP2025148408A (ja) 2019-10-11 2025-07-04 パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物

Country Status (6)

Country Link
US (2) US11779597B2 (enExample)
EP (1) EP4041214A1 (enExample)
JP (3) JP7634895B2 (enExample)
AU (1) AU2019470001B2 (enExample)
CA (1) CA3154392A1 (enExample)
WO (1) WO2021071499A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077524A (zh) * 2023-02-27 2023-05-09 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015185602A1 (en) 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
US10226484B2 (en) 2014-12-01 2019-03-12 Peter Y Novak Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2790926B2 (ja) * 1990-08-20 1998-08-27 エーザイ株式会社 スルホンアミド誘導体
ATE167473T1 (de) * 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
US6162350A (en) 1997-07-15 2000-12-19 Exxon Research And Engineering Company Hydroprocessing using bulk Group VIII/Group VIB catalysts (HEN-9901)
US9861659B2 (en) 2014-12-01 2018-01-09 Vector Vitale Ip Llc Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
KR20180105701A (ko) * 2016-02-11 2018-09-28 모데차이 체비온 신경변성의 치료를 위한 방법 및 약학 조성물
CN106581056A (zh) * 2016-10-11 2017-04-26 徐志强 锌在制造治疗帕金森病药物的用途
US10183041B2 (en) 2017-04-12 2019-01-22 Vector Vitale Ip Llc Antibacterial composition and its use in treating bacterial infections
US10799530B1 (en) 2019-12-20 2020-10-13 Vector Vitale Ip Llc Composition and method for the prevention and treatment of obesity
US10933091B1 (en) 2019-12-20 2021-03-02 Vector Vitale Ip Llc Composition and method for the treatment of type I diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015185602A1 (en) 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
US10226484B2 (en) 2014-12-01 2019-03-12 Peter Y Novak Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof

Also Published As

Publication number Publication date
US12036238B2 (en) 2024-07-16
AU2019470001A1 (en) 2022-05-12
JP2022551943A (ja) 2022-12-14
US11779597B2 (en) 2023-10-10
NZ787735A (en) 2025-03-28
JP2025148408A (ja) 2025-10-07
US20230210894A1 (en) 2023-07-06
CA3154392A1 (en) 2021-04-15
EP4041214A1 (en) 2022-08-17
US20240173350A1 (en) 2024-05-30
JP2024038270A (ja) 2024-03-19
AU2019470001B2 (en) 2024-09-19
WO2021071499A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
Xu et al. 5-(3, 4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1, 2, 4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress
Morroni et al. Early effects of Aβ1-42 oligomers injection in mice: Involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways
Martín et al. Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease
JP5736421B2 (ja) 生理学的過程の調節およびこれに有用な薬剤
JP2021507945A (ja) 認知症を含む神経障害のための組成物および治療方法
US20050147574A1 (en) Inhibitors of proteasomal activity for stimulating hair growth
WO2012027548A1 (en) Compounds and methods for prevention and treatment of alzheimer's and other diseases
JP2025148408A (ja) パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
Askar et al. Effects of exercise and ferulic acid on alpha synuclein and neuroprotective heat shock protein 70 in an experimental model of Parkinsonism disease
Ma et al. Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway
Wang et al. Tricin promoted ATG-7 dependent autophagic degradation of α-synuclein and dopamine release for improving cognitive and motor deficits in Parkinson's disease
JP2012529477A (ja) ５’−メチルチオアデノシンの神経保護特性
Ren et al. Upregulation of thioredoxin contributes to inhibiting diabetic hearing impairment
EP3273978B1 (en) Withania extract for the treatment of amyloid-related diseases
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
Polacchini et al. Antioxidant and anti-ageing effects of oleuropein aglycone in canine skeletal muscle cells
JP2021520413A (ja) 眼科的状態のための療法
Wang et al. Activation of SIRT3 alleviates neurodegeneration via rescuing mitochondrial succinate dehydrogenase activity and bioenergy supply in rotenone-induced PD models
EP1977748B1 (en) Compounds having neuroprotective properties
JP2010539242A (ja) サルコシンレベルを増大させる方法
US20240189312A1 (en) Composition for treating acute brain injury or neurodegenerative disease, method of making, and use thereof
Wang Anthranilate Analogs as a Druggable Target for the Proteopathy and Immunopathy of Alzheimer's Disease
EP4424317A1 (en) Medicine for preventing or treating enteritis and intestinal cancer
TWI722492B (zh) 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途
Ceylan et al. Research on Endoplasmic Reticulum Stress-mediated Protective Effect of Melatonin against Cardiotoxicity Following Cisplatin Treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250204

R150 Certificate of patent or registration of utility model

Ref document number: 7634895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150